Scinai Immunotherapeutics Ltd. SEC filings SCNI
Scinai Immunotherapeutics Ltd. has 495 filings in SEC EDGAR's recent list, going back to Nov 13, 2014. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on May 15, 2023, covering the quarter ended Mar 31, 2023. The most recent current report (Form 6-K) was filed on Oct 20, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Oct 5, 2026 | — |
| EFFECT | Filing | Aug 28, 2026 | — |
| EFFECT | Filing | May 19, 2026 | — |
| CORRESP | Letter to the SEC | May 15, 2026 | — |
| UPLOAD | Letter from the SEC | May 14, 2026 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2025 | — |
| EFFECT | Filing | Sep 8, 2025 | — |
| EFFECT | Filing | May 15, 2025 | — |
| NT 20-F | Notification of late filing | Apr 29, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Mar 12, 2025 | — |
| CORRESP | Letter to the SEC | Mar 11, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| NT 20-F | Notification of late filing | Apr 30, 2024 | Dec 31, 2023 |
| EFFECT | Filing | Feb 13, 2024 | — |
| CORRESP | Letter to the SEC | Feb 9, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 2, 2024 | — |
| D | Filing | Jan 12, 2024 | — |
| EFFECT | Filing | Dec 26, 2023 | — |
| CORRESP | Letter to the SEC | Dec 26, 2023 | — |
| D | Filing | Oct 3, 2023 | — |
| EFFECT | Filing | Aug 25, 2023 | — |
| CORRESP | Letter to the SEC | Aug 23, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2023 | — |
| NT 10-K | Notification of late filing | Apr 3, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Dec 15, 2022 | — |
| CORRESP | Letter to the SEC | Dec 14, 2022 | — |
| CORRESP | Letter to the SEC | Dec 14, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 5, 2022 | — |
| NT 20-F | Notification of late filing | Apr 29, 2021 | Dec 31, 2020 |
| EFFECT | Filing | Aug 10, 2020 | — |
| CORRESP | Letter to the SEC | Aug 6, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2020 | — |
| 25-NSE | Delisting notice | May 13, 2020 | — |
| EFFECT | Filing | Jan 13, 2020 | — |
| EFFECT | Filing | Jun 10, 2019 | — |
| CORRESP | Letter to the SEC | Jun 5, 2019 | — |
| CORRESP | Letter to the SEC | Jun 5, 2019 | — |
| UPLOAD | Letter from the SEC | May 30, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 8, 2019 | — |
| EFFECT | Filing | Feb 2, 2017 | — |
| CORRESP | Letter to the SEC | Feb 2, 2017 | — |
| EFFECT | Filing | Dec 15, 2016 | — |
| CORRESP | Letter to the SEC | Dec 14, 2016 | — |
| DEL AM | Delaying amendment for biondvax pharmaceuticals ltd., registration statement on | Nov 21, 2016 | — |
| CORRESP | Letter to the SEC | Nov 21, 2016 | — |
| EFFECT | Filing | Feb 2, 2016 | — |
| EFFECT | Filing | May 11, 2015 | — |
| EFFECT | Filing | May 11, 2015 | — |
| CORRESP | Letter to the SEC | May 11, 2015 | — |
| CORRESP | Letter to the SEC | May 11, 2015 | — |
| 424A | Prospectus | May 7, 2015 | — |
| CORRESP | Letter to the SEC | May 6, 2015 | — |
| CORRESP | Letter to the SEC | May 6, 2015 | — |
| CORRESP | Letter to the SEC | May 1, 2015 | — |
| CORRESP | Letter to the SEC | May 1, 2015 | — |
| CERTNAS | Auto-generated paper document | Apr 30, 2015 | — |
| 8-A12B/A | Amendment to form 8-a12b | Apr 29, 2015 | — |
| CORRESP | Letter to the SEC | Apr 28, 2015 | — |
| CORRESP | Letter to the SEC | Apr 28, 2015 | — |
| CORRESP | Letter to the SEC | Apr 24, 2015 | — |
| CORRESP | Letter to the SEC | Apr 24, 2015 | — |
| 8-A12B | For registration of certain classes of securities pursuant to section 12(b) | Apr 20, 2015 | — |
| CORRESP | Letter to the SEC | Apr 6, 2015 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2015 | — |
| CORRESP | Letter to the SEC | Dec 29, 2014 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2014 | — |
| DRS | Filing | Nov 13, 2014 | — |
Showing 69 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SCNI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Jerusalem, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1611747
- Former names
- BiondVax Pharmaceuticals Ltd. (until Aug 28, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.